Abstract

Inflammation and cancer are inter-related, and both pro- and anti-tumorigenic effects are possible in different contexts, highlighting the importance of characterizing specific inflammatory pathways in distinct tumor types. Malignant cells and non-cancerous cells such as fibroblasts, infiltrating leukocytes (i.e., dendritic cells [DC], macrophages, or lymphocytes) and endothelial cells, in combination with the extracellular matrix, constitute the tumor microenvironment (TME). In the last decades, the role of the TME in cancer progression has gained increased attention and efforts directed at abrogating its deleterious effects on anti-cancer therapies have been ongoing. In this context, we investigated the potential of mouse and human ovarian cancer cells to produce inflammatory factors in response to pathogen recognition receptor (PRR) signaling, which might help to shape the biology of the TME. We determined that mouse ovarian tumors generate chemokines that are able to interact with receptors harbored by tumor-associated DCs. We also found that dsRNA triggers significant pro-inflammatory cytokine up-regulation in both human and mouse ovarian tumor cell lines, and that several PRR can simultaneously contribute to the stimulated inflammatory response displayed by these cells. Thus, dsRNA-activated PRRs may not only constitute potentially relevant drug targets for therapies aiming to prevent inflammation associated with leukocyte recruitment, or as co-adjuvants of therapeutic treatments, but also might have a role in development of nascent tumors, for example via activation of cancer cells by microbial molecules associated to pathogens, or with those appearing in circulation due to dysbiosis.

Highlights

  • Ovarian cancer is the second most common gynecologic cancer in the US and the fifth leading cause of cancer-related deaths in women

  • We investigated the potential of mouse and human ovarian cancer cells to produce inflammatory factors in response to pathogen recognition receptor (PRR) signaling, which might help to shape the biology of the tumor microenvironment (TME)

  • We investigated the modulation of pro-inflammatory cytokine and chemokine expression by mouse and human ovarian cancer cells upon Double-stranded RNA (dsRNA)-activated PRR signaling through polyinositic:polycytidylic acid or polyadenylic:polyuridylic acid

Read more

Summary

Introduction

Ovarian cancer is the second most common gynecologic cancer in the US and the fifth leading cause of cancer-related deaths in women. Ovarian www.oncotarget.com cancer is typically detected late in the disease process. Due to the commonality of late-stage diagnoses, most cases resulting in death can be attributed to metastasis, the spreading of the tumor from the primary site to distant organs, such as the lungs or liver. Current treatments for ovarian cancer typically involve surgery and chemotherapy (taxane- or platinum-based), but considerable side effects and drug resistance are of major concern as previously reviewed [1, 2]. In addition to research directed at improving diagnostics, it is critical to focus on novel treatment options for late-stage ovarian tumors, in particular those aiming to prevent metastasis

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call